Welcoming 2025 With Innovation, Insights, and Impact

Image Credit: © Sergey Nivens - stock.adobe.com

Welcome, 2025! As we bid farewell to 2024 and look ahead to the New Year, the field of dermatology finds itself on the cusp of yet another exciting year. The past 12 months have been nothing short of transformative, marked by groundbreaking advances, impactful FDA approvals, and a renewed focus on patient-centered care. From novel biologics to cutting-edge devices, the field has evolved in ways that empower clinicians to address the most challenging dermatological conditions with precision and innovation. Dermatology Times is also excited to welcome in a new year of innovations as we close out our 45th year of supporting dermatology clinicians.

In this issue, readers will learn about immunohistochemical stains in Mohs surgery from Nicole A. Negbenebor, MD; systemic therapies for patients with psoriasis with common comorbidities from Karan Lal, DO, MS; and the need for an emphasis on ethics in aesthetics from Samuel Hetz, MD, MSc.

This month’s cover feature takes a deep dive into chronic hand eczema (CHE) with expert insights from Matthew Zirwas, MD; Raj Chovatiya, MD, PhD, MSCI; and Christopher Bunick, MD, PhD. CHE often presents unique challenges for diagnosis and treatment. To better understand its challenging nature, readers can test their knowledge of CHE with questions and commentary from Zirwas, a longtime patch tester and author of one of the few textbook chapters on CHE. Next, catch up on future trends and directions in management by reviewing CHE’s multifactorial etiology and heterogeneous presentation, data presented on the CHECK and RWEAL studies on severity and treatment challenges, and tissue cytokines of TH1 and TH2 in patients with hyperkeratotic CHE.

With the start of the New Year, Dermatology Times is pleased to introduce our 2025 editor in chief, Christopher Bunick, MD, PhD, associate professor of dermatology and translational biomedicine at Yale University School of Medicine in New Haven, Connecticut. Bunick served as one of the quarterly editors in chief in 2024 and has been part of the Dermatology Times editorial advisory board for 4 years. We look forward to the continued contributions of our esteemed editorial advisory board members in another great year.

As always, Dermatology Times provides our readers with the most up-to-date clinical content, from innovative studies and FDA approvals to exclusive interviews and expert insights. Stay informed with the latest data and subscribe to Dermatology Times’ e-newsletters; follow us on Facebook, LinkedIn, and X (formerly Twitter); and email us with ideas or contributions at DTEditor@mmhgroup.com.